CSIMarket
 
Dermata Therapeutics Inc   (DRMA)
Other Ticker:  
 
 
Price: $0.3980 $0.00 -0.872%
Day's High: $0.4098 Week Perf: -8.32 %
Day's Low: $ 0.37 30 Day Perf: -10.1 %
Volume (M): 136 52 Wk High: $ 3.93
Volume (M$): $ 54 52 Wk Avg: $1.11
Open: $0.41 52 Wk Low: $0.37



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Dermata Therapeutics Inc
Dermata Therapeutics Inc is a biopharmaceutical company that specializes in the development and commercialization of novel prescription dermatological products. The company focuses on providing treatments for various skin conditions and diseases, such as psoriasis, atopic dermatitis, acne, and rosacea. Dermata Therapeutics utilizes innovative technologies and scientific research to create effective and safe therapies for patients.


   Company Address: 3525 Del Mar Heights Rd. San Diego 92130 CA
   Company Phone Number: 800-2543   Stock Exchange / Ticker: NASDAQ DRMA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Dermata Therapeutics Inc

Dermata Therapeutics Inc Exhibits Encouraging Progress with Operating Deficit of $-2.446072 Million in Q3 2023



Dermata Therapeutics Inc, a constituent of the Major Pharmaceutical Preparations industry, recently reported its financial results for the third quarter of 2023. Despite a decrease in stock performance over the past five days, there are several positive indicators worth considering. This article will delve into the key financial figures and explore their potential impact on the future of Dermata Therapeutics Inc.
1. Operating Deficit Reduction:
In the most recent fiscal period, Dermata Therapeutics Inc reported an operating deficit of $-1.811978 million. This is a significant improvement compared to the same period in 2022, where the operating deficit was $-2.446072 million. This reduction is a crucial indicator of the company's ability to manage its costs effectively.

Dermata Therapeutics Inc

Dermata Therapeutics Inc Shatters Expectations with Significantly Reduced Operating Loss, Paving the Way for Profitability



As the April to June 2023 reporting cycle unfolds, Dermata Therapeutics Inc, a prominent player in the Major Pharmaceutical Preparations sector, recently disclosed its financial results. The company reported an operating loss of $-1.732414 million for the mentioned period. This noteworthy revelation has generated optimism among market observers, especially considering the improvement from the Q2 2022 operating loss of $-2.730573 million. This article analyzes the potential impacts of these financial results on Dermata Therapeutics Inc's future prospects.
Decreasing Losses:
One of the most intriguing aspects of Dermata Therapeutics Inc's financial results is the substantial decrease in operating losses. Comparing the Q2 2023 loss of $-1.732414 million to the Q2 2022 loss of $-2.731 million, it is evident that the company has made impressive progress in cost management. This reduction reflects the company's commitment to optimizing its operations and aligning them with its long-term goals. Going forward, this trend indicates a potential path to profitability for Dermata Therapeutics Inc.

Dermata Therapeutics Inc

Dermata Therapeutics Inc Breaks New Ground with Impressive First Quarter 2023 Numbers

Dermata Therapeutics Inc is a pharmaceutical company that specializes in dermatology and the development of innovative solutions to treat skin diseases. The company has been operating for several years and has faced its fair share of challenges in a very competitive marketplace.
Over the course of the 12 months leading up to the first quarter of 2023, Dermata Therapeutics Inc recorded a cumulative net loss of $-9 million. This has led to a negative return on assets (ROA) of -100.05%, a concerning figure for stakeholders and investors.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com